{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T08:26:09Z","timestamp":1791707169077,"version":"4.3.4"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T00:00:00Z","timestamp":1587168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MFE 158087"],"award-info":[{"award-number":["MFE 158087"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["MOP 142436"],"award-info":[{"award-number":["MOP 142436"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004376","name":"Terry Fox Research Institute","doi-asserted-by":"publisher","award":["1060"],"award-info":[{"award-number":["1060"]}],"id":[{"id":"10.13039\/501100004376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000161","name":"Networks of Centres of Excellence of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000161","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002879","name":"Canadian HIV Trials Network, Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002879","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000245","name":"Michael Smith Foundation for Health Research","doi-asserted-by":"publisher","award":["16631"],"award-info":[{"award-number":["16631"]}],"id":[{"id":"10.13039\/501100000245","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000147","name":"Canadian Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000147","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009326","name":"Cancer Research Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015803","name":"BC Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015803","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000521","name":"Canadian Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000521","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019265","name":"Carraresi Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014823","name":"VGH and UBC Hospital Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014823","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.ygyno.2020.04.689","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T07:38:04Z","timestamp":1589960284000},"page":"167-177","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers"],"prefix":"10.1016","volume":"158","author":[{"given":"Julian","family":"Smazynski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phineas T.","family":"Hamilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelby","family":"Thornton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Milne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maartje C.A.","family":"Wouters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad H.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2020.04.689_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","article-title":"Immune checkpoint inhibitors: recent progress and potential biomarkers","volume":"50","author":"Darvin","year":"2018","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ygyno.2020.04.689_bb0010","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ctrv.2016.11.007","article-title":"Resistance to PD1\/PDL1 checkpoint inhibition","volume":"52","author":"O\u2019Donnell","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ygyno.2020.04.689_bb0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40425-018-0479-7","article-title":"High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors","volume":"6","author":"Maleki Vareki","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ygyno.2020.04.689_bb0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40661-016-0033-6","article-title":"The role of immune checkpoint inhibition in the treatment of ovarian cancer","volume":"3","author":"Gaillard","year":"2016","journal-title":"Gynecol. Oncol. Res. Pract."},{"key":"10.1016\/j.ygyno.2020.04.689_bb0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0155189","article-title":"Low mutation burden in ovarian cancer may limit the utility of neoantigen-targeted vaccines","volume":"11","author":"Martin","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2020.04.689_bb0030","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ygyno.2016.03.008","article-title":"PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer","volume":"141","author":"Webb","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.04.689_bb0035","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1158\/1078-0432.CCR-15-2762","article-title":"Tumor-infiltrating plasma cells are associated with tertiary lymphoid structures, cytolytic T-cell responses, and superior prognosis in ovarian cancer","volume":"22","author":"Kroeger","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2020.04.689_bb0040","article-title":"Interfaces of malignant and immunologic clonal dynamics in ovarian cancer","author":"Zhang","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ygyno.2020.04.689_bb0045","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2011.09.039","article-title":"Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis","volume":"124","author":"Hwang","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.04.689_bb0050","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41423-018-0168-y","article-title":"Targeting PVR (CD155) and its receptors in anti-tumor therapy","volume":"16","author":"Ku\u010dan Brli\u0107","year":"2019","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ygyno.2020.04.689_bb0055","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","article-title":"The immunoreceptor TIGIT regulates antitumor and antiviral CD8+ T cell effector function","volume":"26","author":"Johnston","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2020.04.689_bb0060","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrm2457","article-title":"Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation","volume":"9","author":"Takai","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ygyno.2020.04.689_bb0065","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1038\/sj.onc.1208409","article-title":"Transcriptional activation of the mouse Necl-5\/Tage 4\/PVR\/CD155 gene by fibroblast growth factor or oncogenic Ras through the Raf\u2013MEK\u2013ERK\u2013AP-1 pathway","volume":"24","author":"Hirota","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2020.04.689_bb0070","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1471-2407-4-73","article-title":"CD155\/PVR plays a key role in cell motility during tumor cell invasion and migration","volume":"4","author":"Sloan","year":"2004","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ygyno.2020.04.689_bb0075","doi-asserted-by":"crossref","first-page":"25697","DOI":"10.1074\/jbc.M201378200","article-title":"Expression of the human poliovirus receptor\/CD155 gene is activated by sonic hedgehog","volume":"277","author":"Solecki","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ygyno.2020.04.689_bb0080","first-page":"3503","article-title":"ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype","volume":"113","author":"Cippitelli","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ygyno.2020.04.689_bb0085","first-page":"2287","article-title":"Clinical significance of CD155 expression in human pancreatic cancer","volume":"35","author":"Nishiwada","year":"2015","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ygyno.2020.04.689_bb0090","first-page":"7312","article-title":"Overexpression of CD155 relates to metastasis and invasion in osteosarcoma","volume":"15","author":"Zhuo","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ygyno.2020.04.689_bb0095","first-page":"2960","article-title":"Survival analysis with regard to PD-L1 and CD155 expression in human small cell lung cancer and a comparison with associated receptors","volume":"17","author":"Xu","year":"2019","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ygyno.2020.04.689_bb0100","doi-asserted-by":"crossref","first-page":"108884","DOI":"10.1016\/j.biopha.2019.108884","article-title":"CD155 expression and its prognostic value in postoperative patients with breast cancer","volume":"115","author":"Yong","year":"2019","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ygyno.2020.04.689_bb0105","doi-asserted-by":"crossref","first-page":"902","DOI":"10.4049\/jimmunol.0903225","article-title":"DNAM-1\/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases","volume":"184","author":"Chan","year":"2010","journal-title":"J. Immunol."},{"key":"10.1016\/j.ygyno.2020.04.689_bb0110","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/imr.12518","article-title":"TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy","volume":"276","author":"Dougall","year":"2017","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ygyno.2020.04.689_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1172\/JCI80445","article-title":"TIGIT and PD-1 impair tumor antigen \u2013 specific CD8 + T cells in melanoma patients","volume":"125","author":"Chauvin","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ygyno.2020.04.689_bb0120","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ccell.2014.11.016","article-title":"TIGIT and CD226: tipping the balance between costimulatory and coinhibitory molecules to augment the cancer immunotherapy toolkit","volume":"26","author":"Pauken","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2020.04.689_bb0125","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1158\/2326-6066.CIR-18-0637","article-title":"CD96 is an immune checkpoint that regulates CD8+ T-cell antitumor function","volume":"7","author":"Mittal","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ygyno.2020.04.689_bb0130","doi-asserted-by":"crossref","first-page":"9020","DOI":"10.1073\/pnas.1818210116","article-title":"Cancer stemness, intratumoral heterogeneity, and immune response across cancers","volume":"116","author":"Miranda","year":"2019","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ygyno.2020.04.689_bb0135","doi-asserted-by":"crossref","DOI":"10.1093\/database\/bat013","article-title":"curated OvarianData: clinically annotated data for the ovarian cancer transcriptome","volume":"2013","author":"Ganzfried","year":"2013","journal-title":"Database"},{"key":"10.1016\/j.ygyno.2020.04.689_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.ygyno.2020.04.689_bb0145","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40425-017-0215-8","article-title":"Gene expression markers of tumor infiltrating leukocytes","volume":"5","author":"Danaher","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ygyno.2020.04.689_bb0150","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1161\/ATVBAHA.111.224162","article-title":"CD155 on human vascular endothelial cells attenuates the acquisition of effector functions in CD8 T cells","volume":"31","author":"Escalante","year":"2011","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ygyno.2020.04.689_bb0155","doi-asserted-by":"crossref","first-page":"847","DOI":"10.3389\/fimmu.2018.00847","article-title":"Interferon-gamma at the crossroads of tumor immune surveillance or evasion","volume":"9","author":"Castro","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ygyno.2020.04.689_bb0160","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/modpathol.2015.133","article-title":"Erratum: beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer","volume":"28","author":"Nawaz","year":"2015","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ygyno.2020.04.689_bb0165","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1538-4632.1992.tb00261.x","article-title":"The analysis of spatial association by use of distance statistics","volume":"24","author":"Getis","year":"2010","journal-title":"Geogr. Anal."},{"key":"10.1016\/j.ygyno.2020.04.689_bb0170","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aat7061","article-title":"Combination cancer immunotherapy targeting PD-1 and GITR can rescue CD8 + T cell dysfunction and maintain memory phenotype","volume":"3","author":"Wang","year":"2018","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.ygyno.2020.04.689_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/2162402X.2018.1445949","article-title":"Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis","volume":"7","author":"Harjunp\u00e4\u00e4","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ygyno.2020.04.689_bb0180","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1479-5876-12-36","article-title":"Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs","volume":"12","author":"Lu","year":"2014","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ygyno.2020.04.689_bb0185","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/nrc4019","article-title":"Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer","volume":"15","author":"Bowtell","year":"2015","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ygyno.2020.04.689_bb0190","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1053\/j.seminoncol.2015.05.011","article-title":"The next hurdle in cancer immunotherapy: overcoming the non\u2013T-cell\u2013inflamed tumor microenvironment","volume":"42","author":"Gajewski","year":"2015","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ygyno.2020.04.689_bb0195","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1172\/JCI98769","article-title":"CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms","volume":"128","author":"Li","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ygyno.2020.04.689_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.semcancer.2019.11.013","article-title":"Tumor intrinsic and extrinsic immune functions of CD155","author":"O\u2019Donnell","year":"2020","journal-title":"Semin. Cancer Biol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820309896?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820309896?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:28:52Z","timestamp":1778664532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820309896"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["S0090825820309896"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.04.689","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.04.689","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}